Latest Hotspot

Electra Therapeutics Unveils Phase 1b Trial Results of ELA026 for sHLH at EHA2024

19 June 2024
3 min read

Electra Therapeutics, Inc., a biotechnology company in the clinical stage, focusing on developing antibody therapies targeting new factors in immunological disorders and cancer, revealed clinical data regarding ELA026 for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

Outcomes have been presented for sHLH patients enrolled in the currently ongoing Phase 1b trial, focusing predominantly on individuals with the most lethal sHLH variant, malignancy-associated HLH. For treatment-naive mHLH patients, ELA026 achieved a complete response rate of 100% by the fourth week and also demonstrated enhanced survival rates at the two-month mark in comparison to historical data. ELA026 showed high efficacy across a broad spectrum of sHLH patients and maintained a favorable safety profile.

ELA026 is an innovative monoclonal antibody that targets signal regulatory protein (SIRP)-α/β1/γ expressed on the surface of myeloid cells and T lymphocytes, which are the pathological immune cells triggering hyperinflammation in sHLH. This Phase 1b trial is an ongoing open-label, multi-dose, single-arm, multicenter study aimed at evaluating the safety and efficacy of ELA026, examining biomarkers, and determining a suitable dose for later Phase 2/3 studies.

"These findings indicate highly encouraging outcomes for ELA026 as a potential treatment for sHLH, a severe disease with devastating impacts on patients and no approved treatments," said Swaminathan P. Iyer, MD, Professor in the Lymphoma/Myeloma Department at The University of Texas MD Anderson Cancer Center. "Importantly, the analysis shows that ELA026 led to improved survival in treatment-naive mHLH patients, highlighting the benefits of early intervention in this rapidly progressing condition," added Swaminathan P. Iyer.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of June 19, 2024, there are 57 investigational drugs for the SIRP targets, including 72 indications, 61 R&D institutions involved, with related clinical trials reaching 58, and as many as 12349 patents.

ELA-026 is a monoclonal antibody drug targeting SIRP and being developed for the treatment of hemic and lymphatic diseases, immune system diseases, and other conditions. With its active indications including lymphohistiocytosis, hemophagocytic, immune system diseases, and inflammation, ELA-026 has the potential to address unmet medical needs in these therapeutic areas. As it progresses through clinical development, Electra Therapeutics, Inc. will continue to advance ELA-026 towards potential approval.

图形用户界面, 文本, 应用程序

描述已自动生成

Cabaletta Bio Announces Positive Early Results for CABA-201 Phase 1/2 Studies in Myositis and SLE
Latest Hotspot
3 min read
Cabaletta Bio Announces Positive Early Results for CABA-201 Phase 1/2 Studies in Myositis and SLE
19 June 2024
Cabaletta Bio Releases Favorable Early Clinical Results from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Studies of CABA-201.
Read →
Kymera Therapeutics Reveals New Phase 1 Trial Data for KT-333 at EHA Event
Latest Hotspot
3 min read
Kymera Therapeutics Reveals New Phase 1 Trial Data for KT-333 at EHA Event
19 June 2024
Kymera Therapeutics Unveils Fresh Clinical Data from Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Event.
Read →
Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
Latest Hotspot
3 min read
Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
19 June 2024
Galapagos unveils promising new results for CD19 CAR-T therapy GLPG5101 in non-Hodgkin lymphoma at EHA 2024.
Read →
FDA Approves Blincyto for CD19-Positive Philadelphia Chromosome-Negative B-ALL in Consolidation Stage
Latest Hotspot
3 min read
FDA Approves Blincyto for CD19-Positive Philadelphia Chromosome-Negative B-ALL in Consolidation Stage
18 June 2024
FDA authorizes Blincyto® (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during consolidation stage.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.